Several GLP-1 receptor agonists, as Liraglutide, have been developed to mimic the glucose-lowering and anorexic effects of Glucagon-like peptide-1 (GLP-1) to treat obesity and T2DM. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.